Stock Market Reviews

INDV (Indivior PLC) News

Get the latest news, insights, and market updates on INDV (Indivior PLC). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations
  AMRN jumps 17% after Q4 and FY2025 preliminary sales beat expectations. The release also reflected positive Q4 cash flow and progress on cost cuts.
  Jan 9, 2026 - $INDV
• Indivior Provides Full-Year 2026 Financial Guidance and Business Update
  Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE® Net Revenue Expected to be in the Range of $905 million to $945 millionNon-GAAP Operating Expenses Expected in the Range of $430 million to $450 millionAdjusted EBITDA Expected in the Range of $535 million to $575 million RICHMOND, Va., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (Nasdaq: INDV) (“Indivior PLC” or the “Company”) today announced its full-year 2026 financial guidance. “2025 was a transiti
  Jan 8, 2026 - $INDV
• GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
  Monte Rosa shares surge 45% after interim phase I data show that MRT-8102 drives deep NEK7 degradation and reduces sharp inflammation markers.
  Jan 8, 2026 - $INDV
• 4 Stocks Trading Near 52-Week High With Room to Rise Further
  Investors target stocks that have been on a bullish run. Stocks like INDV, AUGO, ERO and OI are seeing price strength, and the momentum is likely to continue.
  Jan 8, 2026 - $INDV
• OTLK Stock Crashes 67% in a Week: Here's What You Need to Know
  Outlook Therapeutics stock plunges 67% in a week after the FDA issues a third CRL rejecting its ONS-5010 BLA for wet AMD, again seeking confirmatory data.
  Jan 7, 2026 - $INDV
• Is Indivior (NasdaqGS:INDV) Still Attractive After A 192% One Year Share Price Jump
  If you are wondering whether Indivior's current share price reflects its true worth, this article walks through what the numbers are actually saying about the stock. Indivior's share price, which last closed at US$36.19, comes with returns of 1.3% over the past week, 3.0% over the past month, 1.3% year to date, 191.9% over the past year and 57.3% over three years, with a 417.0% return over five years. This article was prompted to provide ongoing evergreen coverage of Indivior, so the focus...
  Jan 7, 2026 - $INDV
• FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug
  Alkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness.
  Jan 7, 2026 - $INDV
• ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH
  Altimmune shares rally 16.52% after the FDA grants Breakthrough Therapy status to pemvidutide for MASH.
  Jan 6, 2026 - $INDV
• Why This Top 100 Stock to Buy Is Getting Cheaper Even as It Soars Higher
  Virginia-based Indivior, a developer of opioid addiction treatments, continues to hold down a place in Barchart’s Top 100 Stocks to Buy. Up 192% in 2025, its P/E is declining despite the stock’s gains over the past year. Here’s why.
  Dec 30, 2025 - $INDV
• This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table
  When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction.
  Dec 28, 2025 - $INDV